Research on clinical application of Saxagliptin in Chinese type 2 diabetic patients

VernacularTitle:中国2型糖尿病患者沙格列汀临床应用进展
Author: Qing SU
Publication Type:Journal Article
Keywords: Saxagliptin; Dipeptidyl peptidase-4; Efficacy; Safety; Diabetes mellitus,type 2
From: Chinese Journal of Endocrinology and Metabolism 2015;(7):649-652
CountryChina
Language:Chinese
Abstract: Saxagliptin belongs to the class of dipeptidyl peptidase-4(DPP-4) inhibitors which are novel oral glucose-lowering agents with uniquely mechanism in patients with type 2 diabetes mellitus. Clinical efficacy without increasing hypoglycemia of saxagliptin as single agent as well as in combination with other medications used for the treatment of type 2 diabetes mellitus has been well established in several randomized trials. In addition, a cardiovascular outcome study of SAVOR shows that saxagliptin does not increase the risk of a composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death meeting the primary safety objective. The efficacy and safety studies were hereby reviewed.